It's definitely an interesting outcome and nice to see such a significant improvement in a clinical trial.

And as the article states, there are questions that aren't addressed - does the reduction in obstructive events change the clinical symptoms such as daytime sleepiness? Intuitively you would think it does, but it should be measured in the trial. I also didn't see anything about adverse events during the trial. Seems like taking a stimulant might cause insomnia in some patients.

> In addition, 22% of the treated patients achieved complete control of the disease, defined as fewer than five airway obstructing events per hour.

This surprised me - 5 obstructive events per hour is "complete control of the disease"?

It looks like this is the clinical trial: https://clinicaltrials.gov/study/NCT05813275